Skip to Content

ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

At the ESMO 2025 Congress in Berlin, Danny Rischin, MD, from the Peter MacCallum Cancer Centre, presented results from the phase III C-POST trial. In patients with high-risk cutaneous squamous cell carcinoma (SCC) after surgery and radiotherapy, adjuvant cemiplimab reduced the risk of recurrence or death by 68% compared with placebo. The treatment showed a consistent safety profile and supports cemiplimab as a new standard of care in this setting.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top